| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 4,560 | 4,316 | ||
| Prepaid expenses and other current assets | 2,327 | 1,839 | ||
| Loan receivable | 311 | - | ||
| Total current assets | 7,198 | 6,155 | ||
| Property, plant and equipment, net | 16,870 | 16,685 | ||
| Right-of-use asset, net | 4,265 | 4,419 | ||
| Indefinite-lived intangible asset | 1,292 | 1,292 | ||
| Goodwill | 626 | 626 | ||
| Other assets | 358 | 370 | ||
| Total non-current assets | 23,411 | 23,392 | ||
| Total assets | 30,609 | 29,547 | ||
| Accounts payable and accrued expenses | 26,875 | 23,659 | ||
| Accounts payable and accrued expenses to related parties and affiliates | 9,841 | 8,016 | ||
| Convertible notes, net | 818 | 793 | ||
| Convertible notes at fair value | 26,008 | 24,692 | ||
| Notes payable, net | 13,570 | 16,313 | ||
| Warrant liability | - | 681 | ||
| Contingent payable derivative liability | 9,665 | 9,112 | ||
| Investor advances | 207 | 207 | ||
| Share payable | 522 | - | ||
| Lease liabilities | 399 | 448 | ||
| Total current liabilities | 87,905 | 83,921 | ||
| Convertible notes at fair value, net of current portion | 24,617 | 13,772 | ||
| Notes payable, net of current portion, net | 7,188 | 9,166 | ||
| Lease liabilities, net of current portion | 4,447 | 4,624 | ||
| Contingent payment obligation | 1,700 | 4,700 | ||
| Total non-current liabilities | 37,952 | 32,262 | ||
| Total liabilities | 125,857 | 116,183 | ||
| Series c convertible preferred stock, 10,000,000 shares designated 0.8 million and 1.0 million shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively aggregate liquidation preference of 11.7 million-Series CConvertible Preferred Stock | 13,400 | 13,753 | ||
| Common stock (0.001 par value) 1,700,000,000 shares authorized 1,518.3 million and 1,328.6 million shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 1,518 | 1,459 | ||
| Additional paid-in capital | 1,396,179 | 1,378,300 | ||
| Stock subscription receivable | 79 | 79 | ||
| Accumulated deficit | -1,505,049 | -1,478,220 | ||
| Accumulated other comprehensive (loss) income | -1,217 | -1,849 | ||
| Total stockholders' deficit | -108,648 | -100,389 | ||
| Total liabilities, mezzanine equity and stockholders' deficit | 30,609 | 29,547 | ||
NORTHWEST BIOTHERAPEUTICS INC (NWBO)
NORTHWEST BIOTHERAPEUTICS INC (NWBO)